Astrazeneca

FromAstraZeneca ([email protected])
Subject (47)Lynparza granted FDA priority review for PROpel
Preheader (140)Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
Typography
Arial
Colors
Text Analysis
Body Words214
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score0.9
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeOvernight

Lynparza granted FDA priority review for PROpel

Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
Lynparza granted FDA priority review for PROpel